Back to search results
NCT06251973

A Study of agenT-797 in Combination With Botensilimab, Balstilimab, Ramucirumab, and Paclitaxel for People With Esophageal, Gastric, or Gastro-esophageal Junction Cancer

Active, Not Recruiting
PHASE2Ages 18+InterventionalTreatment
Memorial Sloan Kettering Cancer Center
~20 participants
Updated 2026-05-15 on ClinicalTrials.gov
What's tested:AgenT-797BotensilimabBalstilimabRamucirumabPaclitaxel

At a glance

Recruiting sites
0 of 7 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Overall Response Rate
Measured over up to 2 years

Conditions

Metastatic Esophageal Carcinoma
Advanced Unresectable Gastric Adenocarcinoma
Metastatic Gastric Cancer
Metastatic Gastroesophageal Junction Adenocarcinoma
Metastatic Esophageal Cancer
Metastatic Esophageal Adenocarcinoma
Metastatic Gastric Adenocarcinoma
Metastatic Gastric Carcinoma
Unresectable Esophageal Cancer
Unresectable Esophageal Adenocarcinoma
Unresectable Gastric Carcinoma
Unresectable Gastric Adenocarcinoma
Unresectable Gastroesophageal Junction Adenocarcinoma

Explore related trials

Esophageal AdenocarcinomaGastric AdenocarcinomaGastroesophageal Junction Adenocarcinoma

NCT06251973

Where you'd take part

This study runs at 7 sites. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities)

    Basking Ridge, New Jerseyno site contact published

  • Memorial Sloan Kettering Bergen (Limited Protocol Activities)

    Montvale, New Jerseyno site contact published

  • Memorial Sloan Kettering Cancer Center (All Protocol Activities)

    New York, New Yorkno site contact published

  • Memorial Sloan Kettering Monmouth (Limited Protocol Activities)

    Middletown, New Jerseyno site contact published

  • Memorial Sloan Kettering Nassau (Limited Protocol Activities)

    Uniondale, New Yorkno site contact published

  • Memorial Sloan Kettering Suffolk-Commack (Limited protocol activities)

    Commack, New Yorkno site contact published

  • Memorial Sloan Kettering Westchester (Limited Protocol Activities)

    Harrison, New Yorkno site contact published

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Study leadership

  • Yelena Janjigian, MD · PRINCIPAL_INVESTIGATOR · Memorial Sloan Kettering Cancer Center

Who to contact

This trial hasn't published a contact. View it on ClinicalTrials.gov

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Metastatic or advanced unresectable adenocarcinoma of esophageal, gastric, or gastroesophageal junction
Disease progression on one prior line of therapy for metastatic disease. Patients with previously untreated advanced unresectable or metastatic disease may be included if disease progressed or recurred during neoadjuvant or adjuvant therapy or within 6 months of completion of those treatments.
Patients must have histologically or cytologically confirmed esophageal, gastric, or gastroesophageal junction adenocarcinoma
Patients must have measurable or evaluable disease as defined by RECIST v1.1 criteria. Patients with evaluable disease must be eligible to begin with an induction cycle
Age 18 years or older
ECOG performance status 0 to 1
Adequate organ function as defined in Table 2

Exclusion

Received prior therapy with ramucirumab at any time
Received paclitaxel or docetaxel-based therapy within 6 month of study enrollment
Had a prior grade \>3 immune related adverse event due to anti-PD-1, anti-PD-L1, anti-PD-L2, or anti-CTLA4 therapy at any time
Diagnosis of immunodeficiency or receipt of systemic steroid therapy or any other form of immunosuppressive therapy within 7 days before the first dose of trial treatment. Replacement therapy (ie physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency) is not considered a form of systemic immunosuppressive therapy and is allowed.
History of gastrointestinal perforation or fistulae
A known history of active Bacillus tuberculosis
Known active central nervous system metastases and/or carcinomatous meningitis
History of or any evidence of active, non-infectious, immune-mediated pneumonitis. Patients with radiation-induced pneumonitis who are asymptomatic are permitted on study.
Peripheral neuropathy limiting ADLs
A known history of human immunodeficiency virus (HIV 1/2 antibodies)
Known active hepatitis B (e.g., HBsAg reactive) or hepatitis C (e.g., HCV RNA \[qualitative\] is detected). Patients with HBsAg reactive on entecavir may be eligible after consultation with hepatologist and study team.
Received a live vaccine within 30 days of planned start of study therapy
Known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial
Pregnant or breastfeeding or expecting to conceive or father children within the projected duration of the trial, starting with the prescreening or screening visit through 5 months after the last dose of trial treatment
Unwilling to give written, informed consent, unwilling to participate, or unable to comply with the protocol for the duration of the study

What this trial measures

  • Overall Response Rateup to 2 years

    Determine the efficacy of agenT-797, botensilimab and balstilimab in combination with ramucirumab and paclitaxel as second-line therapy in patients with advanced unresectable or metastatic esophagogastric cancer, as measured by ORR (defined as the percentage of patients who achieve either an objective complete response \[CR\] + partial response \[PR\])